Drug Delivery SIG 2
Timeslot: Thursday, April 22, 2021 - 1:45pm to 3:15pm
Track: Therapeutic Delivery
The Drug Delivery Special Interest Group will deal with the science and technology of controlled release of active agents from delivery systems. Controlled drug release is achieved by the use of diffusion, chemical reactions, dissolutions or osmosis, used either singly or in combination. While the vast majority of such delivery devices are based on polymers, controlled release can also be achieved by the use of mechanical pumps. In a broader sense, controlled release also involves control over the site of action of the active agent, using the active agent using pro-drugs, targetable water soluble polymers or various microparticulate systems. Relevant aspects of toxicology, bioavailability, pharmacokinetics, and biocompatibility are also included.
Michael Mitchell, PhD
Omid Veiseh, PhD
Abstracts will be available for download on April 20, 2021.
181. Development of Antimicrobial Biochanin A Poly(beta amino ester) Polymers, Kelley Wiegman1, Michael Flythe2, Zach Hilt1, Thomas Dziubla11University of Kentucky, Lexington, KY, USA, 2U. S. Department of Agriculture, Lexington, KY, USA
182. Bio-responsive Hydrogels for On-Demand Delivery of Anti-Cancer Therapeutics, Fei Fan, Grace Petrosini, Sharon Stack, Donny Hanjaya-PutraUniversity of Notre Dame, Notre Dame, IN, USA
183. Effects of Spatial Organization and Histidine Tag on Efficacy of Intracellular Protein Delivery System, Wei Lv, PhD, Anshul Dhankher, Talmage Studstill, Julie Champion, PhDGeorgia Institute of Technology, Atlanta, GA, USA
184. Drug Release from Ace-DEX Particles: An Experimental and Mathematical Model, Rebeca Stiepel1, Erik Pena2, Matthew Gallovic, PhD3, Christopher Genito4, Eric Bachelder, PhD1, Kristy Ainslie, PhD1,2,41Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC, USA, 3IMMvention Therapeutix, Durham, NC, USA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
185. Using a miR-451 Inhibitor May Mitigate OA Development and Progression In Vivo Following Anterior Cruciate Ligament Injury, Kayla Scott, B.S.1, D. Joshua Cohen, M.D.1, Dane Nielson1, Gloria Kim1, Mark Grinstaff, Ph.D.2, Anisha Joenathan, B.S.2, Brian Snyder, M.D., Ph.D.3, Zvi Schwartz, D.M.D., Ph.D.1,4, Barbara Boyan, Ph.D.1,51Virigina Commonwealth University, Richmond, VA, USA, 2Boston University, Boston, MA, USA, 3Harvard Medical School, Boston, MA, USA, 4University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, 5Georgia Institute of Technology, Georgia, GA, USA
186. Simple Biodegradable Polyester for Stent-Based Drug Delivery, Kathleen Young, Audrey Lord, Susan Kozawa, PhD, Horst von Recum, PhDCase Western Reserve University, Cleveland, OH, USA